About POMALYST® (pomalidomide)
POMALYST, in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Risks of POMALYST
POMALYST has a Boxed Warning for embryo-fetal toxicity and thromboembolic events, including deep venous thrombosis (DVT) and pulmonary embolism (PE), myocardial infarction and stroke. Due to the fact that it is an analogue of thalidomide, a known teratogen, POMALYST is contraindicated in pregnant females or females capable of becoming pregnant. Females of reproductive potential may be treated with POMALYST if they take adequate precautions to avoid pregnancy. Deep Venous Thrombosis (DVT), Pulmonary Embolism (PE), myocardial infarction and stroke occur in patients with multiple myeloma treated with pomalidomide.

This is not a comprehensive description of risks associated with the use of POMALYST. Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.
POMALYST Risk Evaluation and Mitigation Strategy (REMS) program education and prescribing safety kit
1. The prescriber provides comprehensive counseling.

2. The prescriber verifies negative pregnancy test for all female patients of reproductive potential.

3. The prescriber completes POMALYST® (pomalidomide) Patient-Physician Agreement Form with each patient and sends to Celgene.

4. Female patients complete initial mandatory confidential survey by:
   - Visiting www.CelgeneRiskManagement.com
   - Accessing the Celgene REMS mobile app
   - Calling the Celgene Customer Care Center at 1-888-423-5436

Male patients do not need to complete the initial survey.

All patients must complete subsequent mandatory confidential surveys as outlined in the Prescriber Guide to POMALYST REMS® Program.

5. The prescriber completes mandatory confidential survey and receives authorization number by:
   - Visiting www.CelgeneRiskManagement.com
   - Accessing the Celgene REMS mobile app
   - Calling the Celgene Customer Care Center at 1-888-423-5436

6. The prescriber writes POMALYST prescription and includes authorization number and patient risk category.

7. The prescriber sends prescription to certified pharmacy.

This flow sheet should be used only as a quick reference and only after reviewing all of the POMALYST REMS® procedures.

POMALYST is only available under a restricted distribution program, POMALYST REMS®.

© 2017 Celgene Corporation 7/17 REMS-POM16890